MedTrace Logo

Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

NCT01990300 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3281

Last updated 2023-09-18

Study results available
· View outcomes & findings →

Summary

The purpose of this survey is to examine the safety and efficacy of long-term use of alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus determined as warranting combination therapy with alogliptin benzoate and pioglitazone hydrochloride

Conditions

Interventions

DRUG

Alogliptin/Pioglitazone

Alogliptin/Pioglitazone combination tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-28
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Japan

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01990300 on ClinicalTrials.gov